A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT03178552. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
Study identification
- NCT ID
- NCT03178552
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 1,000 participants
Conditions and interventions
Conditions
Interventions
- Alectinib Drug
- Atezolizumab Drug
- Bevacizumab Drug
- Carboplatin Drug
- Cisplatin Drug
- Cobimetinib Drug
- Divarasib Drug
- Docetaxel Drug
- Entrectinib Drug
- Gemcitabine Drug
- Pemetrexed Drug
- Vemurafenib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 21, 2017
- Primary completion
- Oct 30, 2026
- Completion
- Oct 30, 2026
- Last update posted
- Mar 8, 2026
2017 – 2026
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC Davis | Sacramento | California | 95817 | — |
| Rocky Mountain Cancer Center | Denver | Colorado | 80218 | — |
| SCRI Florida Cancer Specialists South | Fort Myers | Florida | 33901 | — |
| Florida Cancer Specialist, North Region | St. Petersburg | Florida | 33705 | — |
| University of Kentucky | Lexington | Kentucky | 40536 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89128 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Weill Cornell Medical College-New York Presbyterian Hospital | New York | New York | 10021 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Oregon HSU | Portland | Oregon | 97210 | — |
| St. Luke's University Health network | Bethlehem | Pennsylvania | 18015 | — |
| Sarah Cannon Research Institute / Tennessee Oncology | Chattanooga | Tennessee | 37404 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 152 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03178552, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 8, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03178552 live on ClinicalTrials.gov.